Walter Becker

Aachen, NW 52074, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Critical role of the CMGC insert sequence for tyrosine autophosphorylation in the protein kinase DYRK1B.

Critical role of the CMGC insert sequence for tyrosine autophosphorylation in the protein kinase DYRK1B.

Journal: Scientific reports

Published: September 26, 2025

The protein kinase DYRK1B is a p53 target gene and functions as a negative feedback regulator of the transcription factor RFX7.

The protein kinase DYRK1B is a p53 target gene and functions as a negative feedback regulator of the transcription factor RFX7.

Journal: Cell death & disease

Published: September 01, 2025

Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signaling.

Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signaling.

Journal: bioRxiv : the preprint server for biology

Published: April 08, 2025

Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B.

Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B.

Journal: Journal of medicinal chemistry

Published: September 30, 2024

Elevated expression levels of the protein kinase DYRK1B induce mesenchymal features in A549 lung cancer cells.

Elevated expression levels of the protein kinase DYRK1B induce mesenchymal features in A549 lung cancer cells.

Journal: BMC cancer

Published: May 07, 2024

Differential regulation of expression of the protein kinases DYRK1A and DYRK1B in cancer cells.

Differential regulation of expression of the protein kinases DYRK1A and DYRK1B in cancer cells.

Journal: Scientific reports

Published: March 20, 2024

Functional characterization of two DYRK1B variants causative of AOMS3.

Functional characterization of two DYRK1B variants causative of AOMS3.

Journal: Orphanet journal of rare diseases

Published: November 29, 2023

Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative Diseases.

Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative Diseases.

Journal: ACS chemical neuroscience

Published: November 02, 2021

Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B.

Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B.

Journal: Scientific reports

Published: September 20, 2021

Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects.

Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects.

Journal: European journal of medicinal chemistry

Published: June 09, 2021

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN.

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN.

Journal: Cancers

Published: June 04, 2021

How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.

How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.

Journal: Molecules (Basel, Switzerland)

Published: November 01, 2020

Showing 1-12 of 31

Last Updated: 09/26/2026